Versatile High Affinity Antibody to DOTA Chelates of Multiple Radionuclides
Compositions and methods for the treatment of cancer and infectious disease The compositions include engineered proteins that specifically bind a target (e g, a cellular protein) on a cancerous cell or a pathogen and a metal chelate comprising DOT A, or an active variant thereof, and a metal ion such as a radionuclide are disclosed By virtue of the multiple binding sites, the engineered protein effectively delivers a metal chelate to a cell one wishes to destroy.
Researchers
-
versatile high affinity antibody to dota chelates of multiple radionuclides
Spain | Granted | 2,403,530 -
engineered proteins with high affinity for dota chelates
United States of America | Granted | 8,648,176 -
versatile high affinity antibody to dota chelates of multiple radionuclides
European Patent Convention | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
Switzerland | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
Italy | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
Ireland | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
United Kingdom | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
Belgium | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
Germany | Granted | 2,403,530 -
versatile high affinity antibody to dota chelates of multiple radionuclides
France | Granted | 2,403,530
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.